×

MN/CA IX/CA9 and Renal Cancer Prognosis

  • US 7,482,129 B2
  • Filed: 05/04/2005
  • Issued: 01/27/2009
  • Est. Priority Date: 05/04/2004
  • Status: Expired due to Fees
First Claim
Patent Images

1. A method which is prognostic for renal cell carcinoma afflicting a vertebrate, said method comprising:

  • (a) detecting the presence or absence of MN/CA IX protein or MN/CA IX polypeptide in a sample comprising neoplastic cells taken from said vertebrate, comprising immunologically assaying said sample with the M75 monoclonal antibody secreted by hybridoma VU-M75 which has Accession No. ATCC HB 11128,(b) if MN/CA IX protein or MN/CA IX polypeptide is present in said sample, quantitating the level and/or extent of said MN/CA IX protein or MN/CA IX polypeptide relative to the number of cells in said sample, and(c) determining that said vertebrate has a prognosis of shorter cumulative survival if the level and/or extent of MN/CA IX protein or MN/CA IX polypeptide of steps (a) and (b) indicates that 50% or fewer of cells in said sample express MN/CA IX protein or MN/CA IX polypeptide;

    wherein said MN/CA IX protein or MN/CA IX polypeptide is encoded by a nucleotide sequence selected from the group consisting of;

    (1) SEQ ID NO;

    1'"'"'s coding region;

    (2) nucleotide sequences that hybridize under stringent hybridization conditions of 50% formamide at 42 degree C. to complement of SEQ ID NO;

    1'"'"'s coding region; and

    (3) nucleotide sequences that differ from SEQ ID NO;

    1'"'"'s coding region or from the nucleotide sequences of (2) in codon sequence due to the degeneracy of the genetic code;

    and wherein said MN/CA IX protein or said MN/CA IX polypeptide is specifically bound by the M75 monoclonal antibody that is secreted from the hybridoma VU-M75 which has Accession No. ATCC HB 11128.

View all claims
  • 5 Assignments
Timeline View
Assignment View
    ×
    ×